A Novel Natural Killer Cell-related Gene Signature for Improving the Prediction of Prognosis and Immunotherapy Response in Bladder Cancer


Cite item

Full Text

Abstract

Background:Bladder cancer (BLCA) is a commonly diagnosed cancer worldwide that exhibits high rates of recurrence and metastasis. Immunotherapy is increasingly being recognised in the clinical management of bladder cancer. In addition, the prospect of developing Natural Killer (NK) cell-related immunotherapy is promising in BLCA.

Methods:We established and verified a prognostic signature based on NK cell-related gene expression. We then calculated the NKscore of BLCA samples and correlated it with the clinical outcomes, molecular subtypes of BLCA, tumour microenvironment (TME), and predicted efficacy of immune checkpoint inhibitors (ICI) and chemotherapy drugs to thoroughly explore the implications of the NKscore. Finally, the role of the NK signature gene HECTD1 in BLCA was verified by Quantitative Real-time PCR, Cell Counting Kit-8 Assay (CCK-8), Transwell Assay and Colony Formation Experiment.

Results:We analysed NK cell-associated genes and identified six genes with significant prognostic relevance. A high NK score significantly represents a worse prognosis. NKscore was significantly correlated with seven types of classical molecular subtype classifications of BLCA. In addition, NKscore positively correlates with NK-related immune checkpoints, suggesting that emerging NK cell immune checkpoint inhibitors, such as monalizumab, may have potential therapeutic promise for patients with high NKscore. The results of the T cell inflamed score (TIS) and tumour immune dysfunction exclusion (TIDE) score confirmed the suitability of immunotherapy for patients with a high NK score. Likewise, patients with a high NK score may be more suitable for several significant chemotherapeutic drugs. Functional experiments showed that the knockdown of HECTD1 significantly attenuated the proliferation, migration, and invasion ability of tumour cells.

Conclusion:To sum up, the capability of our signature to predict prognosis and immunotherapy response was robust. Hopefully, these results will provide new insights for BLCA research and patient immunotherapy.

About the authors

Xudong Ma

Department of Urology, Tianjin Institute of Urology,, The Second Hospital of Tianjin Medical University

Email: info@benthamscience.net

Xifeng Wei

Department of Urology, Tianjin Institute of Urology,, The Second Hospital of Tianjin Medical University

Email: info@benthamscience.net

Guanghua Yang

Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University

Email: info@benthamscience.net

Shuai Li

Department of Urology, Baotou Central Hospital, Inner Mongolia Medical University

Email: info@benthamscience.net

Ranlu Liu

Department of Urology, Tianjin Institute of Urology,, The Second Hospital of Tianjin Medical University

Author for correspondence.
Email: info@benthamscience.net

References

  1. Lenis, A.T.; Lec, P.M.; Chamie, K.; Mshs, M. Bladder Cancer. JAMA, 2020, 324(19), 1980-1991. doi: 10.1001/jama.2020.17598 PMID: 33201207
  2. Rosenberg, J.E.; Hoffman-Censits, J.; Powles, T.; van der Heijden, M.S.; Balar, A.V.; Necchi, A.; Dawson, N.; O’Donnell, P.H.; Balmanoukian, A.; Loriot, Y.; Srinivas, S.; Retz, M.M.; Grivas, P.; Joseph, R.W.; Galsky, M.D.; Fleming, M.T.; Petrylak, D.P.; Perez-Gracia, J.L.; Burris, H.A.; Castellano, D.; Canil, C.; Bellmunt, J.; Bajorin, D.; Nickles, D.; Bourgon, R.; Frampton, G.M.; Cui, N.; Mariathasan, S.; Abidoye, O.; Fine, G.D.; Dreicer, R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet, 2016, 387(10031), 1909-1920. doi: 10.1016/S0140-6736(16)00561-4 PMID: 26952546
  3. Witjes, J.A.; Bruins, H.M.; Cathomas, R.; Compérat, E.M.; Cowan, N.C.; Gakis, G.; Hernández, V.; Linares Espinós, E.; Lorch, A.; Neuzillet, Y.; Rouanne, M.; Thalmann, G.N.; Veskimäe, E.; Ribal, M.J.; van der Heijden, A.G. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines. Eur. Urol., 2021, 79(1), 82-104. doi: 10.1016/j.eururo.2020.03.055 PMID: 32360052
  4. Wu, S.Y.; Fu, T.; Jiang, Y.Z.; Shao, Z.M. Natural killer cells in cancer biology and therapy. Mol. Cancer, 2020, 19(1), 120. doi: 10.1186/s12943-020-01238-x PMID: 32762681
  5. Bald, T.; Krummel, M.F.; Smyth, M.J.; Barry, K.C. The NK cell–cancer cycle: Advances and new challenges in NK cell–based immunotherapies. Nat. Immunol., 2020, 21(8), 835-847. doi: 10.1038/s41590-020-0728-z PMID: 32690952
  6. Guillerey, C.; Huntington, N.D.; Smyth, M.J. Targeting natural killer cells in cancer immunotherapy. Nat. Immunol., 2016, 17(9), 1025-1036. doi: 10.1038/ni.3518 PMID: 27540992
  7. Hodgins, J.J.; Khan, S.T.; Park, M.M.; Auer, R.C.; Ardolino, M. Killers 2.0: NK cell therapies at the forefront of cancer control. J. Clin. Invest., 2019, 129(9), 3499-3510. doi: 10.1172/JCI129338 PMID: 31478911
  8. Ferreira-Teixeira, M.; Paiva-Oliveira, D.; Parada, B.; Alves, V.; Sousa, V.; Chijioke, O.; Münz, C.; Reis, F.; Rodrigues-Santos, P.; Gomes, C. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemo resistant bladder cancer stem-like cells. BMC Med., 2016, 14(1), 163. doi: 10.1186/s12916-016-0715-2 PMID: 27769244
  9. Sun, H.; Huang, Q.; Huang, M.; Wen, H.; Lin, R.; Zheng, M.; Qu, K.; Li, K.; Wei, H.; Xiao, W.; Sun, R.; Tian, Z.; Sun, C. Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma. Hepatology, 2019, 70(1), 168-183. doi: 10.1002/hep.30347 PMID: 30411378
  10. Chauvin, J.M.; Ka, M.; Pagliano, O.; Menna, C.; Ding, Q.; DeBlasio, R.; Sanders, C.; Hou, J.; Li, X.Y.; Ferrone, S.; Davar, D.; Kirkwood, J.M.; Johnston, R.J.; Korman, A.J.; Smyth, M.J.; Zarour, H.M. IL15 stimulation with TIGIT blockade reverses CD155-mediated NK-cell dysfunction in melanoma. Clin. Cancer Res., 2020, 26(20), 5520-5533. doi: 10.1158/1078-0432.CCR-20-0575 PMID: 32591463
  11. Khatua, S.; Cooper, L.J.N.; Sandberg, D.I.; Ketonen, L.; John son, J.M.; Rytting, M.E.; Liu, D.D.; Meador, H.; Trikha, P.; Nakkula, R.J.; Behbehani, G.K.; Ragoonanan, D.; Gupta, S.; Kotrotsou, A.; Idris, T.; Shpall, E.J.; Rezvani, K.; Colen, R.; Zaky, W.; Lee, D.A.; Gopalakrishnan, V. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro-oncol., 2020, 22(8), 1214-1225. doi: 10.1093/neuonc/noaa047 PMID: 32152626
  12. McWilliams, E.M.; Mele, J.M.; Cheney, C.; Timmerman, E.A.; Fiazuddin, F.; Strattan, E.J.; Mo, X.; Byrd, J.C.; Muthusamy, N.; Awan, F.T. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. OncoImmunology, 2016, 5(10), e1226720. doi: 10.1080/2162402X.2016.1226720 PMID: 27853650
  13. Zhang, S.; Liu, W.; Hu, B.; Wang, P.; Lv, X.; Chen, S.; Shao, Z. Prognostic significance of tumor-infiltrating natural killer cells in solid tumors: A systematic review and meta-analysis. Front. Immunol., 2020, 11, 1242. doi: 10.3389/fimmu.2020.01242 PMID: 32714321
  14. Alderdice, M.; Dunne, P.D.; Cole, A.J.; O’Reilly, P.G.; McArt, D.G.; Bingham, V.; Fuchs, M.A.; McQuaid, S.; Loughrey, M.B.; Murray, G.I.; Samuel, L.M.; Lawler, M.; Wilson, R.H.; Salto-Tellez, M.; Coyle, V.M. Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. Mod. Pathol., 2017, 30(9), 1287-1298. doi: 10.1038/modpathol.2017.47 PMID: 28621318
  15. Li, C.; Liu, F.; Sun, L.; Liu, Z.; Zeng, Y. Natural killer cell-related gene signature predicts malignancy of glioma and the survival of patients. BMC Cancer, 2022, 22(1), 230. doi: 10.1186/s12885-022-09230-y PMID: 35236310
  16. Thorsson, V.; Gibbs, D.L.; Brown, S.D.; Wolf, D.; Bortone, D.S.; Ou Yang, T.H.; Porta-Pardo, E.; Gao, G.F.; Plaisier, C.L.; Eddy, J.A.; Ziv, E.; Culhane, A.C.; Paull, E.O.; Sivakumar, I.K.A.; Gentles, A.J.; Malhotra, R.; Farshidfar, F.; Colaprico, A.; Parker, J.S.; Mose, L.E.; Vo, N.S.; Liu, J.; Liu, Y.; Rader, J.; Dhankani, V.; Reynolds, S.M.; Bowlby, R.; Califano, A.; Cherniack, A.D.; Anastassiou, D.; Bedognetti, D.; Mokrab, Y.; Newman, A.M.; Rao, A.; Chen, K.; Krasnitz, A.; Hu, H.; Malta, T.M.; Noushmehr, H.; Pedamallu, C.S.; Bullman, S.; Ojesina, A.I.; Lamb, A.; Zhou, W.; Shen, H.; Choueiri, T.K.; Weinstein, J.N.; Guinney, J.; Saltz, J.; Holt, R.A.; Rabkin, C.S.; Lazar, A.J.; Serody, J.S.; Demicco, E.G.; Disis, M.L.; Vincent, B.G.; Shmulevich, I.; Caesar-Johnson, S.J.; Demchok, J.A.; Felau, I.; Kasapi, M.; Ferguson, M.L.; Hutter, C.M.; Sofia, H.J.; Tarnuzzer, R.; Wang, Z.; Yang, L.; Zenklusen, J.C.; Zhang, J.J.; Chudamani, S.; Liu, J.; Lolla, L.; Naresh, R.; Pihl, T.; Sun, Q.; Wan, Y.; Wu, Y.; Cho, J.; DeFreitas, T.; Frazer, S.; Gehlenborg, N.; Getz, G.; Heiman, D.I.; Kim, J.; Lawrence, M.S.; Lin, P.; Meier, S.; Noble, M.S.; Saksena, G.; Voet, D.; Zhang, H.; Bernard, B.; Chambwe, N.; Dhankani, V.; Knijnenburg, T.; Kramer, R.; Leinonen, K.; Liu, Y.; Miller, M.; Reynolds, S.; Shmulevich, I.; Thorsson, V.; Zhang, W.; Akbani, R.; Broom, B.M.; Hegde, A.M.; Ju, Z.; Kanchi, R.S.; Korkut, A.; Li, J.; Liang, H.; Ling, S.; Liu, W.; Lu, Y.; Mills, G.B.; Ng, K-S.; Rao, A.; Ryan, M.; Wang, J.; Weinstein, J.N.; Zhang, J.; Abeshouse, A.; Armenia, J.; Chakravarty, D.; Chatila, W.K.; de Bruijn, I.; Gao, J.; Gross, B.E.; Heins, Z.J.; Kundra, R.; La, K.; Ladanyi, M.; Luna, A.; Nissan, M.G.; Ochoa, A.; Phillips, S.M.; Reznik, E.; Sanchez-Vega, F.; Sander, C.; Schultz, N.; Sheridan, R.; Sumer, S.O.; Sun, Y.; Taylor, B.S.; Wang, J.; Zhang, H.; Anur, P.; Peto, M.; Spellman, P.; Benz, C.; Stuart, J.M.; Wong, C.K.; Yau, C.; Hayes, D.N.; Parker, J.S.; Wilkerson, M.D.; Ally, A.; Balasundaram, M.; Bowlby, R.; Brooks, D.; Carlsen, R.; Chuah, E.; Dhalla, N.; Holt, R.; Jones, S.J.M.; Kasaian, K.; Lee, D.; Ma, Y.; Marra, M.A.; Mayo, M.; Moore, R.A.; Mungall, A.J.; Mungall, K.; Robertson, A.G.; Sadeghi, S.; Schein, J.E.; Sipahimalani, P.; Tam, A.; Thiessen, N.; Tse, K.; Wong, T.; Berger, A.C.; Beroukhim, R.; Cherniack, A.D.; Cibulskis, C.; Gabriel, S.B.; Gao, G.F.; Ha, G.; Meyerson, M.; Schumacher, S.E.; Shih, J.; Kucherlapati, M.H.; Kucherlapati, R.S.; Baylin, S.; Cope, L.; Danilova, L.; Bootwalla, M.S.; Lai, P.H.; Maglinte, D.T.; Van Den Berg, D.J.; Weisenberger, D.J.; Auman, J.T.; Balu, S.; Bodenheimer, T.; Fan, C.; Hoadley, K.A.; Hoyle, A.P.; Jefferys, S.R.; Jones, C.D.; Meng, S.; Mieczkowski, P.A.; Mose, L.E.; Perou, A.H.; Perou, C.M.; Roach, J.; Shi, Y.; Simons, J.V.; Skelly, T.; Soloway, M.G.; Tan, D.; Veluvolu, U.; Fan, H.; Hinoue, T.; Laird, P.W.; Shen, H.; Zhou, W.; Bellair, M.; Chang, K.; Covington, K.; Creighton, C.J.; Dinh, H.; Doddapaneni, H.V.; Donehower, L.A.; Drummond, J.; Gibbs, R.A.; Glenn, R.; Hale, W.; Han, Y.; Hu, J.; Korchina, V.; Lee, S.; Lewis, L.; Li, W.; Liu, X.; Morgan, M.; Morton, D.; Muzny, D.; Santibanez, J.; Sheth, M.; Shinbrot, E.; Wang, L.; Wang, M.; Wheeler, D.A.; Xi, L.; Zhao, F.; Hess, J.; Appelbaum, E.L.; Bailey, M.; Cordes, M.G.; Ding, L.; Fronick, C.C.; Fulton, L.A.; Fulton, R.S.; Kandoth, C.; Mardis, E.R.; McLellan, M.D.; Miller, C.A.; Schmidt, H.K.; Wilson, R.K.; Crain, D.; Curley, E.; Gardner, J.; Lau, K.; Mallery, D.; Morris, S.; Paulauskis, J.; Penny, R.; Shelton, C.; Shelton, T.; Sherman, M.; Thompson, E.; Yena, P.; Bowen, J.; Gastier-Foster, J.M.; Gerken, M.; Leraas, K.M.; Lichtenberg, T.M.; Ramirez, N.C.; Wise, L.; Zmuda, E.; Corcoran, N.; Costello, T.; Hovens, C.; Carvalho, A.L.; de Carvalho, A.C.; Fregnani, J.H.; Longatto-Filho, A.; Reis, R.M.; Scapulatempo-Neto, C.; Silveira, H.C.S.; Vidal, D.O.; Burnette, A.; Eschbacher, J.; Hermes, B.; Noss, A.; Singh, R.; Anderson, M.L.; Castro, P.D.; Ittmann, M.; Huntsman, D.; Kohl, B.; Le, X.; Thorp, R.; Andry, C.; Duffy, E.R.; Lyadov, V.; Paklina, O.; Setdikova, G.; Shabunin, A.; Tavobilov, M.; McPherson, C.; Warnick, R.; Berkowitz, R.; Cramer, D.; Feltmate, C.; Horowitz, N.; Kibel, A.; Muto, M.; Raut, C.P.; Malykh, A.; Barnholtz-Sloan, J.S.; Barrett, W.; Devine, K.; Fulop, J.; Ostrom, Q.T.; Shimmel, K.; Wolinsky, Y.; Sloan, A.E.; De Rose, A.; Giuliante, F.; Goodman, M.; Karlan, B.Y.; Hagedorn, C.H.; Eckman, J.; Harr, J.; Myers, J.; Tucker, K.; Zach, L.A.; Deyarmin, B.; Hu, H.; Kvecher, L.; Larson, C.; Mural, R.J.; Somiari, S.; Vicha, A.; Zelinka, T.; Bennett, J.; Iacocca, M.; Rabeno, B.; Swanson, P.; Latour, M.; Lacombe, L.; Têtu, B.; Bergeron, A.; McGraw, M.; Staugaitis, S.M.; Chabot, J.; Hibshoosh, H.; Sepulveda, A.; Su, T.; Wang, T.; Potapova, O.; Voronina, O.; Desjardins, L.; Mariani, O.; Roman-Roman, S.; Sastre, X.; Stern, M-H.; Cheng, F.; Signoretti, S.; Berchuck, A.; Bigner, D.; Lipp, E.; Marks, J.; McCall, S.; McLendon, R.; Secord, A.; Sharp, A.; Behera, M.; Brat, D.J.; Chen, A.; Delman, K.; Force, S.; Khuri, F.; Magliocca, K.; Maithel, S.; Olson, J.J.; Owonikoko, T.; Pickens, A.; Ramalingam, S.; Shin, D.M.; Sica, G.; Van Meir, E.G.; Zhang, H.; Eijckenboom, W.; Gillis, A.; Korpershoek, E.; Looijenga, L.; Oosterhuis, W.; Stoop, H.; van Kessel, K.E.; Zwarthoff, E.C.; Calatozzolo, C.; Cuppini, L.; Cuzzubbo, S.; DiMeco, F.; Finocchiaro, G.; Mattei, L.; Perin, A.; Pollo, B.; Chen, C.; Houck, J.; Lohavanichbutr, P.; Hartmann, A.; Stoehr, C.; Stoehr, R.; Taubert, H.; Wach, S.; Wullich, B.; Kycler, W.; Murawa, D.; Wiznerowicz, M.; Chung, K.; Edenfield, W.J.; Martin, J.; Baudin, E.; Bubley, G.; Bueno, R.; De Rienzo, A.; Richards, W.G.; Kalkanis, S.; Mikkelsen, T.; Noushmehr, H.; Scarpace, L.; Girard, N.; Aymerich, M.; Campo, E.; Giné, E.; Guillermo, A.L.; Van Bang, N.; Hanh, P.T.; Phu, B.D.; Tang, Y.; Colman, H.; Evason, K.; Dottino, P.R.; Martignetti, J.A.; Gabra, H.; Juhl, H.; Akeredolu, T.; Stepa, S.; Hoon, D.; Ahn, K.; Kang, K.J.; Beuschlein, F.; Breggia, A.; Birrer, M.; Bell, D.; Borad, M.; Bryce, A.H.; Castle, E.; Chandan, V.; Cheville, J.; Copland, J.A.; Farnell, M.; Flotte, T.; Giama, N.; Ho, T.; Kendrick, M.; Kocher, J-P.; Kopp, K.; Moser, C.; Nagorney, D.; O’Brien, D.; O’Neill, B.P.; Patel, T.; Petersen, G.; Que, F.; Rivera, M.; Roberts, L.; Smallridge, R.; Smyrk, T.; Stanton, M.; Thompson, R.H.; Torbenson, M.; Yang, J.D.; Zhang, L.; Brimo, F.; Ajani, J.A.; Gonzalez, A.M.A.; Behrens, C.; Bondaruk, J.; Broaddus, R.; Czerniak, B.; Esmaeli, B.; Fujimoto, J.; Gershenwald, J.; Guo, C.; Lazar, A.J.; Logothetis, C.; Meric-Bernstam, F.; Moran, C.; Ramondetta, L.; Rice, D.; Sood, A.; Tamboli, P.; Thompson, T.; Troncoso, P.; Tsao, A.; Wistuba, I.; Carter, C.; Haydu, L.; Hersey, P.; Jakrot, V.; Kakavand, H.; Kefford, R.; Lee, K.; Long, G.; Mann, G.; Quinn, M.; Saw, R.; Scolyer, R.; Shannon, K.; Spillane, A.; Stretch,; Synott, M.; Thompson, J.; Wilmott, J.; Al-Ahmadie, H.; Chan, T.A.; Ghossein, R.; Gopalan, A.; Levine, D.A.; Reuter, V.; Singer, S.; Singh, B.; Tien, N.V.; Broudy, T.; Mirsaidi, C.; Nair, P.; Drwiega, P.; Miller, J.; Smith, J.; Zaren, H.; Park, J-W.; Hung, N.P.; Kebebew, E.; Linehan, W.M.; Metwalli, A.R.; Pacak, K.; Pinto, P.A.; Schiffman, M.; Schmidt, L.S.; Vocke, C.D.; Wentzensen, N.; Worrell, R.; Yang, H.; Moncrieff, M.; Goparaju, C.; Melamed, J.; Pass, H.; Botnariuc, N.; Caraman, I.; Cernat, M.; Chemencedji, I.; Clipca, A.; Doruc, S.; Gorincioi, G.; Mura, S.; Pirtac, M.; Stancul, I.; Tcaciuc, D.; Albert, M.; Alexopoulou, I.; Arnaout, A.; Bartlett, J.; Engel, J.; Gilbert, S.; Parfitt, J.; Sekhon, H.; Thomas, G.; Rassl, D.M.; Rintoul, R.C.; Bifulco, C.; Tamakawa, R.; Urba, W.; Hayward, N.; Timmers, H.; Antenucci, A.; Facciolo, F.; Grazi, G.; Marino, M.; Merola, R.; de Krijger, R.; Gimenez-Roqueplo, A-P.; Piché, A.; Chevalier, S.; McKercher, G.; Birsoy, K.; Barnett, G.; Brewer, C.; Farver, C.; Naska, T.; Pennell, N.A.; Raymond, D.; Schilero, C.; Smolenski, K.; Williams, F.; Morrison, C.; Borgia, J.A.; Liptay, M.J.; Pool, M.; Seder, C.W.; Junker, K.; Omberg, L.; Dinkin, M.; Manikhas, G.; Alvaro, D.; Bragazzi, M.C.; Cardinale, V.; Carpino, G.; Gaudio, E.; Chesla, D.; Cottingham, S.; Dubina, M.; Moiseenko, F.; Dhanasekaran, R.; Becker, K-F.; Janssen, K-P.; Slotta-Huspenina, J.; Abdel-Rahman, M.H.; Aziz, D.; Bell, S.; Cebulla, C.M.; Davis, A.; Duell, R.; Elder, J.B.; Hilty, J.; Kumar, B.; Lang, J.; Lehman, N.L.; Mandt, R.; Nguyen, P.; Pilarski, R.; Rai, K.; Schoenfield, L.; Senecal, K.; Wakely, P.; Hansen, P.; Lechan, R.; Powers, J.; Tischler, A.; Grizzle, W.E.; Sexton, K.C.; Kastl, A.; Henderson, J.; Porten, S.; Waldmann, J.; Fassnacht, M.; Asa, S.L.; Schadendorf, D.; Couce, M.; Graefen, M.; Huland, H.; Sauter, G.; Schlomm, T.; Simon, R.; Tennstedt, P.; Olabode, O.; Nelson, M.; Bathe, O.; Carroll, P.R.; Chan, J.M.; Disaia, P.; Glenn, P.; Kelley, R.K.; Landen, C.N.; Phillips, J.; Prados, M.; Simko, J.; Smith-McCune, K.; VandenBerg, S.; Roggin, K.; Fehrenbach, A.; Kendler, A.; Sifri, S.; Steele, R.; Jimeno, A.; Carey, F.; Forgie, I.; Mannelli, M.; Carney, M.; Hernandez, B.; Campos, B.; Herold-Mende, C.; Jungk, C.; Unterberg, A.; von Deimling, A.; Bossler, A.; Galbraith, J.; Jacobus, L.; Knudson, M.; Knutson, T.; Ma, D.; Milhem, M.; Sigmund, R.; Godwin, A.K.; Madan, R.; Rosenthal, H.G.; Adebamowo, C.; Adebamowo, S.N.; Boussioutas, A.; Beer, D.; Giordano, T.; Mes-Masson, A-M.; Saad, F.; Bocklage, T.; Landrum, L.; Mannel, R.; Moore, K.; Moxley, K.; Postier, R.; Walker, J.; Zuna, R.; Feldman, M.; Valdivieso, F.; Dhir, R.; Luketich, J.; Pinero, E.M.M.; Quintero-Aguilo, M.; Carlotti, C.G., Jr; Dos Santos, J.S.; Kemp, R.; Sankarankuty, A.; Tirapelli, D.; Catto, J.; Agnew, K.; Swisher, E.; Creaney, J.; Robinson, B.; Shelley, C.S.; Godwin, E.M.; Kendall, S.; Shipman, C.; Bradford, C.; Carey, T.; Haddad, A.; Moyer, J.; Peterson, L.; Prince, M.; Rozek, L.; Wolf, G.; Bowman, R.; Fong, K.M.; Yang, I.; Korst, R.; Rathmell, W.K.; Fantacone-Campbell, J.L.; Hooke, J.A.; Kovatich, A.J.; Shriver, C.D.; DiPersio, J.; Drake, B.; Govindan, R.; Heath, S.; Ley, T.; Van Tine, B.; Westervelt, P.; Rubin, M.A.; Lee, J.I.; Aredes, N.D.; Mariamidze, A. The immune landscape of cancer. Immunity, 2018, 48(4), 812-830.e14. doi: 10.1016/j.immuni.2018.03.023 PMID: 29628290
  17. Gaudet, P.; Škunca, N.; Hu, J.C.; Dessimoz, C. Primer on the gene ontology. Methods Mol. Biol., 2017, 1446, 25-37. doi: 10.1007/978-1-4939-3743-1_3 PMID: 27812933
  18. Kanehisa, M.; Furumichi, M.; Tanabe, M.; Sato, Y.; Morishima, K. KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res., 2017, 45(D1), D353-D361. doi: 10.1093/nar/gkw1092 PMID: 27899662
  19. Yu, G.; Wang, L.G.; Han, Y.; He, Q.Y. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS, 2012, 16(5), 284-287. doi: 10.1089/omi.2011.0118 PMID: 22455463
  20. Choi, W.; Porten, S.; Kim, S.; Willis, D.; Plimack, E.R.; Hoffman-Censits, J.; Roth, B.; Cheng, T.; Tran, M.; Lee, I.L.; Melquist, J.; Bondaruk, J.; Majewski, T.; Zhang, S.; Pretzsch, S.; Baggerly, K.; Siefker-Radtke, A.; Czerniak, B.; Dinney, C.P.N.; McConkey, D.J. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell, 2014, 25(2), 152-165. doi: 10.1016/j.ccr.2014.01.009 PMID: 24525232
  21. Damrauer, J.S.; Hoadley, K.A.; Chism, D.D.; Fan, C.; Tiganelli, C.J.; Wobker, S.E.; Yeh, J.J.; Milowsky, M.I.; Iyer, G.; Parker, J.S.; Kim, W.Y. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl. Acad. Sci., 2014, 111(8), 3110-3115. doi: 10.1073/pnas.1318376111 PMID: 24520177
  22. Mo, Q.; Nikolos, F.; Chen, F.; Tramel, Z.; Lee, Y.C.; Hayashi, K.; Xiao, J.; Shen, J.; Chan, K.S. Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas. J. Natl. Cancer Inst., 2018, 110(5), 448-459. doi: 10.1093/jnci/djx243 PMID: 29342309
  23. Kamoun, A.; de Reyniès, A.; Allory, Y.; Sjödahl, G.; Robertson, A.G.; Seiler, R.; Hoadley, K.A.; Groeneveld, C.S.; Al-Ahmadie, H.; Choi, W.; Castro, M.A.A.; Fontugne, J.; Eriksson, P.; Mo, Q.; Kardos, J.; Zlotta, A.; Hartmann, A.; Dinney, C.P.; Bellmunt, J.; Powles, T.; Malats, N.; Chan, K.S.; Kim, W.Y.; McConkey, D.J.; Black, P.C.; Dyrskjøt, L.; Höglund, M.; Lerner, S.P.; Real, F.X.; Radvanyi, F.; Aine, M.; Al-Ahmadie, H.; Allory, Y.; Bellmunt, J.; Bernard-Pierrot, I.; Black, P.C.; Castro, M.A.A.; Chan, K.S.; Choi, W.; Czerniak, B.; Dinney, C.P.; Dyrskjøt, L.; Eriksson, P.; Fontugne, J.; Gibb, E.A.; Groeneveld, C.S.; Hartmann, A.; Hoadley, K.A.; Höglund, M.; Kamoun, A.; Kardos, J.; Kim, J.; Kim, W.Y.; Kwiatkowski, D.J.; Lebret, T.; Lerner, S.P.; Liedberg, F.; Malats, N.; McConkey, D.J.; Mo, Q.; Powles, T.; Radvanyi, F.; Real, F.X.; de Reyniès, A.; Robertson, A.G.; Siefker-Radtke, A.; Sirab, N.; Seiler, R.; Sjödahl, G.; Taber, A.; Weinstein, J.; Zlotta, A. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol., 2020, 77(4), 420-433. doi: 10.1016/j.eururo.2019.09.006 PMID: 31563503
  24. Robertson, A.G.; Kim, J.; Al-Ahmadie, H.; Bellmunt, J.; Guo, G.; Cherniack, A.D.; Hinoue, T.; Laird, P.W.; Hoadley, K.A.; Akbani, R.; Castro, M.A.A.; Gibb, E.A.; Kanchi, R.S.; Gordenin, D.A.; Shukla, S.A.; Sanchez-Vega, F.; Hansel, D.E.; Czerniak, B.A.; Reuter, V.E.; Su, X.; de Sa Carvalho, B.; Chagas, V.S.; Mungall, K.L.; Sadeghi, S.; Pedamallu, C.S.; Lu, Y.; Klimczak, L.J.; Zhang, J.; Choo, C.; Ojesina, A.I.; Bullman, S.; Leraas, K.M.; Lichtenberg, T.M.; Wu, C.J.; Schultz, N.; Getz, G.; Meyerson, M.; Mills, G.B.; McConkey, D.J.; Weinstein, J.N.; Kwiatkowski, D.J.; Lerner, S.P. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cancer Cell, 2018, 174(4), 1033. PMID: 30096301
  25. Rebouissou, S.; Bernard-Pierrot, I.; de Reyniès, A.; Lepage, M.L.; Krucker, C.; Chapeaublanc, E.; Hérault, A.; Kamoun, A.; Caillault, A.; Letouzé, E.; Elarouci, N.; Neuzillet, Y.; Denoux, Y.; Molinié, V.; Vordos, D.; Laplanche, A.; Maillé, P.; Soyeux, P.; Ofualuka, K.; Reyal, F.; Biton, A.; Sibony, M.; Paoletti, X.; Southgate, J.; Benhamou, S.; Lebret, T.; Allory, Y.; Radvanyi, F. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci. Transl. Med., 2014, 6(244), 244ra91. doi: 10.1126/scitranslmed.3008970 PMID: 25009231
  26. Sjödahl, G.; Lauss, M.; Lövgren, K.; Chebil, G.; Gudjonsson, S.; Veerla, S.; Patschan, O.; Aine, M.; Fernö, M.; Ringnér, M.; Månsson, W.; Liedberg, F.; Lindgren, D.; Höglund, M. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res., 2012, 18(12), 3377-3386. doi: 10.1158/1078-0432.CCR-12-0077-T PMID: 22553347
  27. Hänzelmann, S.; Castelo, R.; Guinney, J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics, 2013, 14(1), 7. doi: 10.1186/1471-2105-14-7 PMID: 23323831
  28. Mayakonda, A.; Lin, D.C.; Assenov, Y.; Plass, C.; Koeffler, H.P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res., 2018, 28(11), 1747-1756. doi: 10.1101/gr.239244.118 PMID: 30341162
  29. Bindea, G.; Mlecnik, B.; Tosolini, M.; Kirilovsky, A.; Waldner, M.; Obenauf, A.C.; Angell, H.; Fredriksen, T.; Lafontaine, L.; Berger, A.; Bruneval, P.; Fridman, W.H.; Becker, C.; Pagès, F.; Speicher, M.R.; Trajanoski, Z.; Galon, J. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity, 2013, 39(4), 782-795. doi: 10.1016/j.immuni.2013.10.003 PMID: 24138885
  30. Newman, A.M.; Liu, C.L.; Green, M.R.; Gentles, A.J.; Feng, W.; Xu, Y.; Hoang, C.D.; Diehn, M.; Alizadeh, A.A. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods, 2015, 12(5), 453-457. doi: 10.1038/nmeth.3337 PMID: 25822800
  31. Yoshihara, K.; Shahmoradgoli, M.; Martínez, E.; Vegesna, R.; Kim, H.; Torres-Garcia, W.; Treviño, V.; Shen, H.; Laird, P.W.; Levine, D.A.; Carter, S.L.; Getz, G.; Stemke-Hale, K.; Mills, G.B.; Verhaak, R.G.W. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun., 2013, 4(1), 2612. doi: 10.1038/ncomms3612 PMID: 24113773
  32. Mariathasan, S.; Turley, S.J.; Nickles, D.; Castiglioni, A.; Yuen, K.; Wang, Y.; Kadel, E.E., III; Koeppen, H.; Astarita, J.L.; Cubas, R.; Jhunjhunwala, S.; Banchereau, R.; Yang, Y.; Guan, Y.; Chalouni, C.; Ziai, J.; Şenbabaoğlu, Y.; Santoro, S.; Sheinson, D.; Hung, J.; Giltnane, J.M.; Pierce, A.A.; Mesh, K.; Lianoglou, S.; Riegler, J.; Carano, R.A.D.; Eriksson, P.; Höglund, M.; Somarriba, L.; Halligan, D.L.; van der Heijden, M.S.; Loriot, Y.; Rosenberg, J.E.; Fong, L.; Mellman, I.; Chen, D.S.; Green, M.; Derleth, C.; Fine, G.D.; Hegde, P.S.; Bourgon, R.; Powles, T. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature, 2018, 554(7693), 544-548. doi: 10.1038/nature25501 PMID: 29443960
  33. Ayers, M.; Lunceford, J.; Nebozhyn, M.; Murphy, E.; Loboda, A.; Kaufman, D.R.; Albright, A.; Cheng, J.D.; Kang, S.P.; Shankaran, V.; Piha-Paul, S.A.; Yearley, J.; Seiwert, T.Y.; Ribas, A.; McClanahan, T.K. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest., 2017, 127(8), 2930-2940. doi: 10.1172/JCI91190 PMID: 28650338
  34. Fu, J.; Li, K.; Zhang, W.; Wan, C.; Zhang, J.; Jiang, P.; Liu, X.S. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med., 2020, 12(1), 21. doi: 10.1186/s13073-020-0721-z PMID: 32102694
  35. Geeleher, P.; Cox, N.; Huang, R.S. pRRophetic: An R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One, 2014, 9(9), e107468. doi: 10.1371/journal.pone.0107468 PMID: 25229481
  36. Gao, J.; Zheng, Q.; Xin, N.; Wang, W.; Zhao, C. CD 155, an onco‐immunologic molecule in human tumors. Cancer Sci., 2017, 108(10), 1934-1938. doi: 10.1111/cas.13324 PMID: 28730595
  37. Lupo, K.B.; Matosevic, S. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. J. Hematol. Oncol., 2020, 13(1), 76. doi: 10.1186/s13045-020-00913-2 PMID: 32532329
  38. Kearney, C.J.; Ramsbottom, K.M.; Voskoboinik, I.; Darcy, P.K.; Oliaro, J. Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing. Onco Immunology, 2016, 5(8), e1196308. doi: 10.1080/2162402X.2016.1196308 PMID: 27622064
  39. Zhang, J.; Zhu, Y.; Wang, Q.; Kong, Y.; Sheng, H.; Guo, J.; Xu, J.; Dai, B. Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis. Urol. Oncol., 2020, 38(2), 41.e11-41.e18. doi: 10.1016/j.urolonc.2019.07.006 PMID: 31383549
  40. Luo, C.; Ye, W.; Hu, J.; Othmane, B.; Li, H.; Chen, J.; Zu, X. A poliovirus receptor (CD155)-related risk signature predicts the prognosis of bladder cancer. Front. Oncol., 2021, 11, 660273. doi: 10.3389/fonc.2021.660273 PMID: 34150627
  41. Li, X.; Zhou, Q.; Sunkara, M.; Kutys, M.L.; Wu, Z.; Rychahou, P.; Morris, A.J.; Zhu, H.; Evers, B.M.; Huang, C. Ubiquitylation of phosphatidylinositol 4-phosphate 5-kinase type I γ by HECTD1 regulates focal adhesion dynamics and cell migration. J. Cell Sci., 2013, 126(Pt 12), 2617-2628. PMID: 23572508
  42. Bennett, L.; Madders, E.C.E.T.; Parsons, J.L. HECTD1 promotes base excision repair in nucleosomes through chromatin remodelling. Nucleic Acids Res., 2020, 48(3), 1301-1313. doi: 10.1093/nar/gkz1129 PMID: 31799632
  43. de Curtis, I. The Rac3 GTPase in neuronal development, neurodevelopmental disorders, and cancer. Cells, 2019, 8(9), 1063. doi: 10.3390/cells8091063 PMID: 31514269
  44. Sun, S.; Wang, Y.; Wang, J.; Bi, J. Wnt pathway-related three mRNA clinical outcome signature in bladder urothelial carcinoma: computational biology and experimental analyses. J. Transl. Med., 2021, 19(1), 409. doi: 10.1186/s12967-021-03061-4 PMID: 34579753
  45. Zhu, W.L.; Hossain, M.S.; Guo, D.Y.; Liu, S.; Tong, H.; Khakpoor, A.; Casey, P.J.; Wang, M. A role for Rac3 GTPase in the regulation of autophagy. J. Biol. Chem., 2011, 286(40), 35291-35298. doi: 10.1074/jbc.M111.280990 PMID: 21852230
  46. Rao, A.; Luo, C.; Hogan, P.G. Transcription factors of the nfat family:Regulation and function. Annu. Rev. Immunol., 1997, 15(1), 707-747. doi: 10.1146/annurev.immunol.15.1.707 PMID: 9143705
  47. Peng, S.L.; Gerth, A.J.; Ranger, A.M.; Glimcher, L.H. NFATc1 and NFATc2 together control both T and B cell acti-vation and differentiation. Immunity, 2001, 14(1), 13-20. doi: 10.1016/S1074-7613(01)00085-1 PMID: 11163226
  48. Heim, L.; Friedrich, J.; Engelhardt, M.; Trufa, D.I.; Geppert, C.I.; Rieker, R.J.; Sirbu, H.; Finotto, S. NFATc1 promotes antitumoral effector functions and memory CD8+ T-cell differentiation during non–small cell lung cancer development. Cancer Res., 2018, 78(13), 3619-3633. doi: 10.1158/0008-5472.CAN-17-3297 PMID: 29691251
  49. Tsai, F.Y.; Keller, G.; Kuo, F.C.; Weiss, M.; Chen, J.; Rosenblatt, M.; Alt, F.W.; Orkin, S.H. An early haematopoietic defect in micelacking the transcription factor GATA-2. Nature, 1994, 371(6494), 221-226. doi: 10.1038/371221a0 PMID: 8078582
  50. Katerndahl, C.D.S.; Rogers, O.R.S.; Day, R.B.; Cai, M.A.; Rooney, T.P.; Helton, N.M.; Hoock, M.; Ramakrishnan, S.M.; Nonavinkere Srivatsan, S.; Wartman, L.D.; Miller, C.A.; Ley, T.J. Tumor suppressor function of Gata2 in acute promyelocytic leukemia. Blood, 2021, 138(13), 1148-1161. doi: 10.1182/blood.2021011758 PMID: 34125173
  51. Mace, E.M.; Hsu, A.P.; Monaco-Shawver, L.; Makedonas, G.; Rosen, J.B.; Dropulic, L.; Cohen, J.I.; Frenkel, E.P.; Bagwell, J.C.; Sullivan, J.L.; Biron, C.A.; Spalding, C.; Zerbe, C.S.; Uzel, G.; Holland, S.M.; Orange, J.S. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56bright subset. Blood, 2013, 121(14), 2669-2677. doi: 10.1182/blood-2012-09-453969 PMID: 23365458
  52. Dell’Angelica, E.C. The building BLOC(k)s of lysosomes and related organelles. Curr. Opin. Cell Biol., 2004, 16(4), 458-464. doi: 10.1016/j.ceb.2004.05.001 PMID: 15261680
  53. Morgan, N.V.; Pasha, S.; Johnson, C.A.; Ainsworth, J.R.; Eady, R.A.J.; Dawood, B.; McKeown, C.; Trembath, R.C.; Wilde, J.; Watson, S.P.; Maher, E.R. A germline mutation in BLOC1S3/reduced pigmentation causes a novel variant of Hermansky-Pudlak syndrome (HPS8). Am. J. Hum. Genet., 2006, 78(1), 160-166. doi: 10.1086/499338 PMID: 16385460
  54. Balar, A.V.; Kamat, A.M.; Kulkarni, G.S.; Uchio, E.M.; Boormans, J.L.; Roumiguié, M.; Krieger, L.E.M.; Singer, E.A.; Bajorin, D.F.; Grivas, P.; Seo, H.K.; Nishiyama, H.; Konety, B.R.; Li, H.; Nam, K.; Kapadia, E.; Frenkl, T.; de Wit, R. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study. Lancet Oncol., 2021, 22(7), 919-930. doi: 10.1016/S1470-2045(21)00147-9 PMID: 34051177
  55. Li, M.O.; Wolf, N.; Raulet, D.H.; Akkari, L.; Pittet, M.J.; Ro-driguez, P.C.; Kaplan, R.N.; Munitz, A.; Zhang, Z.; Cheng, S.; Bhardwaj, N. Innate immune cells in the tumor microenvironment. Cancer Cell, 2021, 39(6), 725-729. doi: 10.1016/j.ccell.2021.05.016 PMID: 34129817
  56. Ranti, D.; Bieber, C.; Wang, Y.S.; Sfakianos, J.P.; Horowitz, A. Natural killer cells: Unlocking new treatments for bladder cancer. Trends Cancer, 2022, 8(8), 698-710. doi: 10.1016/j.trecan.2022.03.007 PMID: 35581130
  57. Rosenberg, J.; Huang, J. CD8+ T cells and NK cells: Parallel and complementary soldiers of immunotherapy. Curr. Opin. Chem. Eng., 2018, 19, 9-20. doi: 10.1016/j.coche.2017.11.006 PMID: 29623254
  58. Tsujihashi, H.; Matsuda, H.; Uejima, S.; Akiyama, T.; Kurita, T. Role of natural killer cells in bladder tumor. Eur. Urol., 1989, 16(6), 444-449. doi: 10.1159/000471637 PMID: 2591428
  59. Moretta, A.; Biassoni, R.; Bottino, C.; Pende, D.; Vitale, M.; Poggi, A.; Mingari, M.C.; Moretta, L. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol. Rev., 1997, 155(1), 105-117. doi: 10.1111/j.1600-065X.1997.tb00943.x PMID: 9059886
  60. Buckle, I.; Guillerey, C. Inhibitory receptors and immune checkpoints regulating natural killer cell responses to cancer. Cancers., 2021, 13(17), 4263. doi: 10.3390/cancers13174263 PMID: 34503073
  61. Khan, M.; Arooj, S.; Wang, H. NK cell-based immune check point inhibition. Front. Immunol., 2020, 11, 167. doi: 10.3389/fimmu.2020.00167 PMID: 32117298
  62. Galot, R.; Le Tourneau, C.; Saada-Bouzid, E.; Daste, A.; Even, C.; Debruyne, P.; Henry, S.; Zanetta, S.; Rutten, A.; Licitra, L.; Canon, J.L.; Kaminsky, M.C.; Specenier, P.; Rottey, S.; Guigay, J.; Kong, A.; Tinhofer, I.; Borcoman, E.; Dirix, L.; Raveloarivahy, T.; Fortpied, C.; Vanlancker, M.; Morfouace, M.; Govaerts, A.S.; Machiels, J.P. A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. Eur. J. Cancer, 2021, 158, 17-26. doi: 10.1016/j.ejca.2021.09.003 PMID: 34638090
  63. Ruggeri, L.; Urbani, E.; André, P.; Mancusi, A.; Tosti, A.; Topini, F.; Bléry, M.; Animobono, L.; Romagné, F.; Wagtmann, N.; Velardi, A. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. Haematologica, 2016, 101(5), 626-633. doi: 10.3324/haematol.2015.135301 PMID: 26721894
  64. Jandus, C.; Boligan, K.F.; Chijioke, O.; Liu, H.; Dahlhaus, M.; Démoulins, T.; Schneider, C.; Wehrli, M.; Hunger, R.E.; Baerlocher, G.M.; Simon, H.U.; Romero, P.; Münz, C.; von Gunten, S. Interactions between Siglec-7/9 receptors and ligands influence NK cell–dependent tumor immunosurveillance. J. Clin. Invest., 2014, 124(4), 1810-1820. doi: 10.1172/JCI65899 PMID: 24569453
  65. Matlung, H.L.; Szilagyi, K.; Barclay, N.A.; van den Berg, T.K. The CD47-SIRPα signaling axis as an innate immune check point in cancer. Immunol. Rev., 2017, 276(1), 145-164. doi: 10.1111/imr.12527 PMID: 28258703

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers